GlassScriptPhysician profile
Matthew Stromberg
NPI 1922888429
$7,763.12
in general payments reported to CMS, 2019-2025
18 companies · $4,153 in 2025
The $4,153 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $250 · 2024: $3,360 · 2025: $4,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,651 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,651.47 |
| Education | $111.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,322.28 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $1,211.45 | 2024-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $948.25 | 2023-2025 | Caplyta |
| Abbvie INC. | $823.51 | 2024-2025 | |
| Alkermes, INC. | $668.18 | 2024-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $586.13 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $569.30 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $314.87 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $310.08 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $217.45 | 2023-2025 | Trintellix |
| Lundbeck LLC | $205.20 | 2024-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $146.07 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $116.40 | 2024-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $103.01 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $89.62 | 2024-2025 | Fanapt |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $67.64 | 2025 | Onyda Xr, Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $46.55 | 2023-2024 | Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $17.13 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Stromberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.